Tradename: VAXNEUVANCE
Proper Name: Pneumococcal 15-valent Conjugate Vaccine
Indication: To include results from study V114-022 in the “Use in Specific Populations” section of the package insert, for pediatric and adult recipients of allogenic hematopoietic stem-cell transplant (allo-HSCT).
VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.
Approval Date: 05/25/2023
Manufacturer: Merck Sharp & Dohme LLC
More: https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance